28235687|t|Immodin and its immune system supportive role in paclitaxel therapy of 4T1 mouse breast cancer
28235687|a|It is evident that standard chemotherapy agents may have an impact on both tumor and host immune system. Paclitaxel (PTX), a very potent anticancer drug from a taxane family, has achieved prominence in clinical oncology for its efficacy against a wide range of tumors including breast cancer. However, significant toxicity, such as myelosuppression, limit the effectiveness of Paclitaxel -based treatment regimens. Immodin (IM) is low molecular dialysate fraction of homogenate made from human leukocytes. It contains a mixture of substances from which so far have been described e.g. Imreg 1 and Imreg 2 formed by the dipeptide tyrosine-glycine and the tripeptide tyrosine-glycine-glycine, respectively. The aim of this study was to explore immunopharmacological activities of IM, using the strongly immunogenic 4T1 mouse breast cancer model, and evaluate its effect on the reactivity and the efficiency of PTX cancer therapy. The results highlight a potentially beneficial role for IM in alleviating PTX - induced toxicity, especially on the nonspecific immunity, during breast cancer therapy. Co-treatment exhibited an antitumor effect including reduced tumor growth, prolonged survival of tumor bearing mice, increased number of monocytes and lymphocytes in peripheral blood. In spleens, IM + PTX therapy elevated proportion of whole lymphocytes in the account of myelo-monocytic cells characteristic with low expression of CD11c+ and bearing Fc receptor (CD16 / 32) as well as T-lymphocytes, NK cells and dendritic cells. Accumulation of tumor - associated granulocytes in stroma of PTX - treated group and intensive 4T1 - necrosis / apoptosis in tumors after co-treatment were also recorded. These findings suggest the possibility of using IM alongside PTX treatment for maintaining the immune system functions and increasing patient survival.
28235687	0	7	Immodin	T103	UMLS:C1254351
28235687	16	29	immune system	T022	UMLS:C0020962
28235687	49	59	paclitaxel	T103	UMLS:C0144576
28235687	60	67	therapy	T058	UMLS:C0087111
28235687	71	80	4T1 mouse	T038	UMLS:C2986594
28235687	81	94	breast cancer	T038	UMLS:C0678222
28235687	123	142	chemotherapy agents	T103	UMLS:C0003392
28235687	170	175	tumor	T038	UMLS:C0027651
28235687	185	198	immune system	T022	UMLS:C0020962
28235687	200	210	Paclitaxel	T103	UMLS:C0144576
28235687	212	215	PTX	T103	UMLS:C0144576
28235687	232	247	anticancer drug	T103	UMLS:C0003392
28235687	255	261	taxane	T103	UMLS:C0215136
28235687	297	314	clinical oncology	T091	UMLS:C1274034
28235687	356	362	tumors	T038	UMLS:C0027651
28235687	373	386	breast cancer	T038	UMLS:C0678222
28235687	409	417	toxicity	T037	UMLS:C0600688
28235687	427	443	myelosuppression	T033	UMLS:C0854467
28235687	472	482	Paclitaxel	T103	UMLS:C0144576
28235687	490	508	treatment regimens	T058	UMLS:C0040808
28235687	510	517	Immodin	T103	UMLS:C1254351
28235687	519	521	IM	T103	UMLS:C1254351
28235687	540	558	dialysate fraction	T103	UMLS:C0011947
28235687	583	588	human	T204	UMLS:C0086418
28235687	589	599	leukocytes	T017	UMLS:C0023516
28235687	680	687	Imreg 1	T103	UMLS:C0063442
28235687	692	699	Imreg 2	T103	UMLS:C0030956
28235687	714	723	dipeptide	T103	UMLS:C0012512
28235687	724	740	tyrosine-glycine	T103	UMLS:C0012512
28235687	749	759	tripeptide	T103	UMLS:C0030956
28235687	760	784	tyrosine-glycine-glycine	T103	UMLS:C0030956
28235687	816	821	study	T062	UMLS:C2603343
28235687	873	875	IM	T103	UMLS:C1254351
28235687	908	917	4T1 mouse	T038	UMLS:C2986594
28235687	918	931	breast cancer	T038	UMLS:C0678222
28235687	1003	1006	PTX	T103	UMLS:C0144576
28235687	1007	1021	cancer therapy	T058	UMLS:C0920425
28235687	1079	1081	IM	T103	UMLS:C1254351
28235687	1097	1100	PTX	T103	UMLS:C0144576
28235687	1111	1119	toxicity	T037	UMLS:C0600688
28235687	1151	1159	immunity	T038	UMLS:C0020964
28235687	1168	1181	breast cancer	T038	UMLS:C0678222
28235687	1182	1189	therapy	T058	UMLS:C0087111
28235687	1288	1293	tumor	T038	UMLS:C0027651
28235687	1302	1306	mice	T038	UMLS:C2986594
28235687	1328	1337	monocytes	T017	UMLS:C0026473
28235687	1342	1353	lymphocytes	T017	UMLS:C0024264
28235687	1357	1373	peripheral blood	T031	UMLS:C0229664
28235687	1387	1389	IM	T103	UMLS:C1254351
28235687	1392	1395	PTX	T103	UMLS:C0144576
28235687	1396	1403	therapy	T058	UMLS:C0087111
28235687	1433	1444	lymphocytes	T017	UMLS:C0024264
28235687	1463	1484	myelo-monocytic cells	T017	UMLS:C0229659
28235687	1509	1519	expression	T038	UMLS:C1171362
28235687	1523	1529	CD11c+	T103	UMLS:C0023395
28235687	1542	1553	Fc receptor	T103	UMLS:C0034805
28235687	1555	1559	CD16	T103	UMLS:C0108747
28235687	1562	1564	32	T103	UMLS:C0054951
28235687	1577	1590	T-lymphocytes	T017	UMLS:C0039194
28235687	1592	1600	NK cells	T017	UMLS:C0022688
28235687	1605	1620	dendritic cells	T017	UMLS:C0011306
28235687	1622	1634	Accumulation	T033	UMLS:C4055506
28235687	1638	1643	tumor	T038	UMLS:C0027651
28235687	1657	1669	granulocytes	T017	UMLS:C0018183
28235687	1673	1679	stroma	T017	UMLS:C0927195
28235687	1683	1686	PTX	T103	UMLS:C0144576
28235687	1717	1720	4T1	T017	UMLS:C0597032
28235687	1723	1731	necrosis	T038	UMLS:C0027540
28235687	1734	1743	apoptosis	T038	UMLS:C0162638
28235687	1747	1753	tumors	T038	UMLS:C0027651
28235687	1783	1791	recorded	T170	UMLS:C0034869
28235687	1799	1807	findings	T033	UMLS:C0243095
28235687	1841	1843	IM	T103	UMLS:C1254351
28235687	1854	1857	PTX	T103	UMLS:C0144576
28235687	1858	1867	treatment	T058	UMLS:C0087111
28235687	1888	1901	immune system	T022	UMLS:C0020962